Find the right people at the right drug companies, and know the best week to call them. For a fraction of what a full database costs.
Big pharma databases are built for analysts and strategy teams. You pay for drug pipelines, market reports and hundreds of thousands of records. BD mostly uses one thing: contacts.
A big list is not the same as the right names. BD needs the person who makes the decision, at a company that is ready to spend, with an email that actually works.
The root cause: you are paying for a giant database when BD only needs a small part of it. A tool built just for that part can be sharper and much cheaper.
Drug companies whose work fits what Jubilant does best: the right stage, type of drug, disease area and region.
You choose which job titles matter, for each BD team: Discovery, ADC & Biologics, API & CDMO, Pharma research partnering, and investors.
A real reason to call this week, with a link to the proof. Every email opens with something the buyer cares about.
Most databases only solve the first one. The value is in solving all three at once.
Every company comes with its trigger and a link to the filing or announcement behind it.
3 to 8 people per company, matched to the job titles each BD team picks.
Every email shows when it was last checked. Old contacts are re-checked, not padded.
One click to your CRM or a spreadsheet. No export limits, no credits to ration.
Tap any signal to see how a first email could open.
The US government is due to publish its first list of restricted biotech companies under the BIOSECURE Act around 18 December 2026. US biotechs that use a listed CRO will need new partners, and Indian CROs are expected to gain about USD 700M a year. We can find your most exposed prospects before the list comes out.
The data licences are in Jubilant's name. If you ever stop working with us, the data stays with you.
Contacts are looked up when there is a reason to call, not bought in bulk and left to go stale.
Company filings, clinical trials, research papers, patents and press releases, checked every day.
The 3,000–7,000 drug companies that fit what Jubilant offers.
Funding, deals, new programmes and new leaders, ranked into a weekly call list.
The right job titles, from 2–3 trusted data providers, checked before you see them.
Sent to your CRM with the reason to call and its source attached.
Pick 3 segments and about 100 companies with your BD team. Choose the job titles.
About 300 decision-makers, every email checked.
A “why now” for every company. You spot-check 50 contacts.
Compare with what you get today, then decide yes or no.
Which companies and job titles matter most to each BD team.
A few companies you already target, so we can compare like for like.
So the pilot ends before your current contract renews, and you decide with real results.